Ruixiang X. Zhang

No.127 Dongming Road
Zhengzhou, 450008, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma.

Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma.

Journal: Journal for immunotherapy of cancer

Published: April 01, 2026

Oriented Tiny Object Detection: A Dataset, Benchmark, and Dynamic Unbiased Learning.

Oriented Tiny Object Detection: A Dataset, Benchmark, and Dynamic Unbiased Learning.

Journal: IEEE transactions on pattern analysis and machine intelligence

Published: November 18, 2025

Validation and refinement of the AJCC 8th edition ypStage in esophageal squamous cell carcinoma after neoadjuvant therapy: a large-scale retrospective cohort study.

Validation and refinement of the AJCC 8th edition ypStage in esophageal squamous cell carcinoma after neoadjuvant therapy: a large-scale retrospective cohort study.

Journal: International journal of surgery (London, England)

Published: September 30, 2025

Survival and Perioperative Outcomes After Addition of Immunotherapy to Neoadjuvant Chemoradiotherapy for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma.

Survival and Perioperative Outcomes After Addition of Immunotherapy to Neoadjuvant Chemoradiotherapy for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma.

Journal: Thoracic cancer

Published: November 13, 2024

S-1-based concurrent chemoradiotherapy plus nimotuzumab in patients with locally advanced esophageal squamous cell carcinoma who failed neoadjuvant therapy: a real-world prospective study.

S-1-based concurrent chemoradiotherapy plus nimotuzumab in patients with locally advanced esophageal squamous cell carcinoma who failed neoadjuvant therapy: a real-world prospective study.

Journal: Cancer biology & therapy

Published: October 27, 2024

Lymph Node Metastasis for pN+ Superficial Esophageal Squamous Cell Carcinoma.

Lymph Node Metastasis for pN+ Superficial Esophageal Squamous Cell Carcinoma.

Journal: Thoracic cancer

Published: September 22, 2024

A multicenter prospective clinical trial reveals cell-free DNA methylation markers for early esophageal cancer.

A multicenter prospective clinical trial reveals cell-free DNA methylation markers for early esophageal cancer.

Journal: The Journal of clinical investigation

Published: September 18, 2024

Development and validation of the systemic nutrition/inflammation index for improving perioperative management of non-small cell lung cancer.

Development and validation of the systemic nutrition/inflammation index for improving perioperative management of non-small cell lung cancer.

Journal: BMC medicine

Published: August 27, 2024

Conversion chemoradiotherapy combined with nab-paclitaxel plus cisplatin in patients with locally advanced borderline-resectable or unresectable esophageal squamous cell carcinoma: a phase i/ii prospective cohort study.

Conversion chemoradiotherapy combined with nab-paclitaxel plus cisplatin in patients with locally advanced borderline-resectable or unresectable esophageal squamous cell carcinoma: a phase i/ii prospective cohort study.

Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]

Published: May 16, 2024

Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial.

Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 17, 2024

Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.

Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.

Journal: Nature medicine

Published: March 29, 2024

Collaborative multidisciplinary management and expertise of cT2-3 locally advanced operable esophageal squamous cell carcinoma: a report of two cases.

Collaborative multidisciplinary management and expertise of cT2-3 locally advanced operable esophageal squamous cell carcinoma: a report of two cases.

Journal: Journal of thoracic disease

Published: August 15, 2023

Showing 1-12 of 59

Last Updated: 09/26/2026